102 related articles for article (PubMed ID: 25834916)
81. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O
Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375
[TBL] [Abstract][Full Text] [Related]
82. Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study.
Kayahashi K; Mizumoto Y; Matsuoka A; Obata T; Iwadare J; Nakamura M; Daikoku T; Fujiwara H
BMC Cancer; 2021 Jan; 21(1):32. PubMed ID: 33413178
[TBL] [Abstract][Full Text] [Related]
83. Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer.
Yin M; Li C; Li X; Lou G; Miao B; Liu X; Meng F; Zhang H; Chen X; Sun M; Ling Q; Zhou R
J Surg Oncol; 2011 Jul; 104(1):29-36. PubMed ID: 21416470
[TBL] [Abstract][Full Text] [Related]
84. A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma.
Aoki D; Katsumata N; Nakanishi T; Kigawa J; Fujiwara K; Takehara K; Kamiura S; Hiura M; Hatae M; Sugiyama T; Ochiai K; Noda K
Jpn J Clin Oncol; 2011 Mar; 41(3):320-7. PubMed ID: 20974678
[TBL] [Abstract][Full Text] [Related]
85. Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.
Mittempergher L
Curr Oncol Rep; 2016 Jul; 18(7):44. PubMed ID: 27241520
[TBL] [Abstract][Full Text] [Related]
86. Individualized chemotherapeutic regimen for each histological subtype of ovarian carcinoma.
Shimizu Y
Gan To Kagaku Ryoho; 1997 May; 24 Suppl 1():61-9. PubMed ID: 9210889
[TBL] [Abstract][Full Text] [Related]
87. Rhabdomyosarcoma arising in a mature cystic teratoma with contralateral serous carcinoma: case report and review of the literature.
Kefeli M; Kandemir B; Akpolat I; Yildirim A; Kokcu A
Int J Gynecol Pathol; 2009 Jul; 28(4):372-5. PubMed ID: 19483625
[TBL] [Abstract][Full Text] [Related]
88. Better therapeutic trials in ovarian cancer.
Bookman MA; Gilks CB; Kohn EC; Kaplan KO; Huntsman D; Aghajanian C; Birrer MJ; Ledermann JA; Oza AM; Swenerton KD
J Natl Cancer Inst; 2014 Apr; 106(4):dju029. PubMed ID: 24627272
[TBL] [Abstract][Full Text] [Related]
89. Mucinous ovarian cancer: A therapeutic review.
Xu W; Rush J; Rickett K; Coward JI
Crit Rev Oncol Hematol; 2016 Jun; 102():26-36. PubMed ID: 27083591
[TBL] [Abstract][Full Text] [Related]
90. Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary.
McLachlan J; Gore M; Banerjee S
Pharmacogenomics; 2016 Aug; 17(12):1353-63. PubMed ID: 27469379
[TBL] [Abstract][Full Text] [Related]
91. Low-grade Serous Tumors: Are We Making Progress?
Pauly N; Ehmann S; Ricciardi E; Ataseven B; Bommert M; Heitz F; Prader S; Schneider S; du Bois A; Harter P; Baert T
Curr Oncol Rep; 2020 Jan; 22(1):8. PubMed ID: 31989304
[TBL] [Abstract][Full Text] [Related]
92. Update on nonserous ovarian cancer trials.
Fujiwara K; Yoshida H; Hasegawa K
Ann Oncol; 2013 Dec; 24 Suppl 10():x46-x47. PubMed ID: 24265404
[No Abstract] [Full Text] [Related]
93. Ethics of chemotherapy during pregnancy.
Fancher KM; Giannetti V; McLaughlin BT
Am J Health Syst Pharm; 2019 Feb; 76(4):242-246. PubMed ID: 30715184
[No Abstract] [Full Text] [Related]
94. [Low-grade serous, mucinous carcinoma].
Nakayama K; Kyo S
Gan To Kagaku Ryoho; 2015 Feb; 42(2):179-82. PubMed ID: 25834916
[No Abstract] [Full Text] [Related]
95. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
96. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates.
Gurung A; Hung T; Morin J; Gilks CB
Histopathology; 2013 Jan; 62(1):59-70. PubMed ID: 23240670
[TBL] [Abstract][Full Text] [Related]
97.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
98.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
99.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
